Gilead Sciences (NASDAQ:GILD – Get Free Report) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17, Briefing.com reports. Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The firm had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. During the same quarter last year, the company posted $1.37 EPS. The firm’s quarterly revenue was up 5.3% on a year-over-year basis. Gilead Sciences updated its FY24 guidance to $3.45-3.85 EPS and its FY 2024 guidance to 3.450-3.850 EPS.
Gilead Sciences Stock Down 2.7 %
GILD traded down $1.81 during trading on Thursday, hitting $65.27. The company had a trading volume of 15,163,484 shares, compared to its average volume of 7,415,576. The company has a market cap of $81.27 billion, a PE ratio of 14.98, a P/E/G ratio of 0.96 and a beta of 0.19. Gilead Sciences has a 1-year low of $65.09 and a 1-year high of $87.86. The business has a 50-day moving average of $71.56 and a 200-day moving average of $76.39. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27.
Gilead Sciences Increases Dividend
The company also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were given a dividend of $0.77 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.72%. The ex-dividend date of this dividend was Thursday, March 14th. Gilead Sciences’s payout ratio is presently 68.44%.
Wall Street Analyst Weigh In
Get Our Latest Stock Report on GILD
Insiders Place Their Bets
In other news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total transaction of $146,360.00. Following the completion of the transaction, the insider now owns 100,936 shares in the company, valued at $7,386,496.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is owned by corporate insiders.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More
- Five stocks we like better than Gilead Sciences
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Hasbro’s Management Made All the Right Calls This Quarter
- What Investors Need to Know About Upcoming IPOs
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.